Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.

Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.

Approximately 25% of kidney transplant recipients develop de novo anti-HLA donor-specific antibodies (dnDSA) leading to acute antibody-mediated rejection (ABMR) in 30% of patients. Preemptive therapeutic strategies are not available.We conducted a prospective observational study including 11 kidney...

Full description

Bibliographic Details
Main Authors: Marie Matignon, Caroline Pilon, Morgane Commereuc, Cynthia Grondin, Claire Leibler, Tomek Kofman, Vincent Audard, José Cohen, Florence Canoui-Poitrine, Philippe Grimbert
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5487035?pdf=render

Internet

http://europepmc.org/articles/PMC5487035?pdf=render

Similar Items